Bashir, Mustafa R.

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Harrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., et al. (2019) · The Lancet

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 802

Deep learning in radiology: An overview of the concepts and a survey of the state of the art with focus on MRI

Mazurowski, M. A., Buda, M., Saha, A., & Bashir, M. R. (2019) · Journal of Magnetic Resonance Imaging

Artificial Intelligence in Healthcare and EducationRadiomics and Machine Learning in Medical Imaging

Cited by 554

Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial

Harrison, S. A., Taub, R., Neff, G. W., Lucas, K. J., Labriola, D., Moussa, S. E., Alkhouri, N., & Bashir, M. R. (2023) · Nature Medicine

Liver Disease Diagnosis and TreatmentHepatitis C virus research

Cited by 435

NGM282 for treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Harrison, S. A., Rinella, M. E., Abdelmalek, M. F., Trotter, J. F., Paredes, A. H., Arnold, H. L., Kugelmas, M., Bashir, M. R., Jaros, M. J., Ling, L., et al. (2018) · The Lancet

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 425

Current and potential imaging applications of ferumoxytol for magnetic resonance imaging

Toth, G. B., Varallyay, C. G., Horvath, A., Bashir, M. R., Choyke, P. L., Daldrup-Link, H. E., Dosa, E., Finn, J. P., Gahramanov, S., Harisinghani, M., et al. (2017) · Kidney International

Advanced MRI Techniques and ApplicationsLanthanide and Transition Metal Complexes

Cited by 317

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis

Harrison, S. A., Neff, G., Guy, C. D., Bashir, M. R., Paredes, A. H., Frias, J. P., Younes, Z., Trotter, J. F., Gunn, N. T., Moussa, S. E., et al. (2021) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 280

Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage

Siddiqui, M. S., Yamada, G., Vuppalanchi, R., Van Natta, M., Loomba, R., Guy, C., Brandman, D., Tonascia, J., Chalasani, N., Neuschwander-Tetri, B., et al. (2019) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 272

NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis

Harrison, S. A., Rossi, S. J., Paredes, A. H., Trotter, J. F., Bashir, M. R., Guy, C. D., Banerjee, R., Jaros, M. J., Owers, S., Baxter, B. A., et al. (2020) · Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 262

Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH

Harrison, S. A., Bashir, M., Moussa, S. E., McCarty, K., Pablo Frias, J., Taub, R., & Alkhouri, N. (2021) · Hepatology Communications

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 197

Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study

Huang, D. Q., Wilson, L. A., Behling, C., Kleiner, D. E., Kowdley, K. V., Dasarathy, S., Amangurbanova, M., Terrault, N. A., Diehl, A. M., Chalasani, N., et al. (2023) · Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 190

The Project Baseline Health Study: a step towards a broader mission to map human health

Arges, K., Assimes, T., Bajaj, V., Balu, S., Bashir, M. R., Beskow, L., Blanco, R., Califf, R., Campbell, P., Carin, L., et al. (2020) · npj Digital Medicine

Health, Environment, Cognitive AgingArtificial Intelligence in Healthcare and Education

Cited by 82

Impact of Reference Standard on CT, MRI, and Contrast-enhanced US LI-RADS Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis

van der Pol, C. B., McInnes, M. D. F., Salameh, J.-P., Chernyak, V., Tang, A., Bashir, M. R., for the LI-RADS IPD Group, Allen, B. C., Burke, L. M. B., Choi, J.-Y., et al. (2022) · Radiology

Hepatocellular Carcinoma Treatment and PrognosisRadiomics and Machine Learning in Medical Imaging

Cited by 38

Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis

Harrison, S. A., Neff, G., Guy, C., Bashir, M., Paredes, A., Frias, J., Younes, Z. H., Trotter, J. F., Gunn, N. T., Moussa, S., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 1